Sigma Planning Corp Buys 2,115 Shares of Liquidia Co. (NASDAQ:LQDA)

Sigma Planning Corp grew its position in Liquidia Co. (NASDAQ:LQDA) by 3.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 65,210 shares of the company’s stock after acquiring an additional 2,115 shares during the period. Sigma Planning Corp owned 0.08% of Liquidia worth $767,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Catalina Capital Group LLC raised its position in Liquidia by 6.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock valued at $215,000 after purchasing an additional 1,125 shares during the last quarter. DMC Group LLC raised its holdings in Liquidia by 17.4% in the 4th quarter. DMC Group LLC now owns 16,302 shares of the company’s stock valued at $192,000 after buying an additional 2,419 shares during the last quarter. Rhumbline Advisers boosted its position in Liquidia by 3.5% during the 4th quarter. Rhumbline Advisers now owns 80,652 shares of the company’s stock worth $948,000 after buying an additional 2,741 shares during the period. Walleye Trading LLC increased its position in Liquidia by 54.7% in the 3rd quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock valued at $132,000 after acquiring an additional 4,670 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Liquidia by 43.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company’s stock valued at $187,000 after acquiring an additional 5,669 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Insider Buying and Selling at Liquidia

In related news, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the completion of the sale, the general counsel now directly owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Roger Jeffs sold 22,343 shares of the business’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $263,200.54. Following the transaction, the chief executive officer now owns 1,019,177 shares in the company, valued at approximately $12,005,905.06. This trade represents a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,945 shares of company stock valued at $874,403. Corporate insiders own 30.10% of the company’s stock.

Analysts Set New Price Targets

LQDA has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Wells Fargo & Company started coverage on Liquidia in a research report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Liquidia in a report on Thursday, January 9th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $25.38.

Liquidia Stock Performance

Liquidia stock opened at $15.45 on Wednesday. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.99. The stock’s 50 day moving average price is $13.67 and its two-hundred day moving average price is $11.69. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -9.48 and a beta of 0.27.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).